|
T9920 |
Evolocumab
|
|
Others
|
|
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). |
|
T31611 |
Eldacimibe
|
WAY-ACA-147,UNII-4PBL76O2G8,ANA 147,ACA 147 |
Acyltransferase
|
|
Eldacimibe (WAY-ACA-147) is an ACAT2 inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, study of atherosclerosis and hypercholesterolemia. |
|
T25276 |
Crilvastatin
|
PMD387,PMD 387,PMD-387 |
HMG-CoA Reductase
|
|
Crilvastatin (PMD 387) is a novel non-competitive hydroxymethylglutaryl coenzyme A reductase inhibitor with cholesterol-lowering activity that inhibits cholesterol uptake in rats with hereditary hypercholesterolemia. |
|
T4509 |
Inositol nicotinate
|
Inositol niacinate,Hexanicotol,Myo-Inositol hexanicotinate,Mesotal,Dilexpal,Inositol hexanicotinate |
Others
|
|
Inositol nicotinate (Mesotal) has the effect of lowering cholesterol and expanding peripheral blood vessels for hypercholesterolemia and atherosclerosis. |
|
T27832 |
Lifibrol
|
U 83860,K-12148,K-12.148,U-83860,K12148 |
Lipid
|
|
Lifibrol (U-83860) is an inhibitor of cholesterol synthesis.Lifibrol has anticholesterol and hypolipidemic properties and promotes the conversion of LDL Apo B-100 in patients with hypercholesterolemia and mixed hyperlipi... |
|
T76739 |
Bococizumab
|
RN316,PF-04950615 |
Others
|
|
Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to... |
|
T76941 |
Carotuximab
|
DE-122,TRC105 |
TGF-beta/Smad
,
Immunology/Inflammation related
|
|
Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab h... |
|
T30977 |
Clofibride
|
|
|
|
Clofibrin is a kind of hypolipidemic drug, which can reduce Hypertriglyceride and hypercholesterolemia. |
|
T27565 |
Hyzetimibe
|
HS25,HS 25,HS-25 |
|
|
Hyzetimibe, a cholesterol absorption blocker, is used potentially for the treatment of hypercholesterolemia. |
|
T28440 |
PPD 10558
|
PPD-10558,RBx10558,RBx-10558,PPD10558,RBx 10558 |
|
|
PPD 10558, a HMG-CoA reductase inhibitor, is used potentially for treatment of primary hypercholesterolemia. |
|
T26182 |
Seladelpar lysine
|
MBX-8025 lysine dihydrate,MBX-8025 Lysine,MBX 8025 Lysine MBX8025 Lysine |
|
|
Seladelpar lysine, a selective PPAR-δ agonist, is used for the therapy of Homozygous Familial Hypercholesterolemia (HoFH). |
|
T27245 |
(RS)-Eflucimibe
|
F12511,L-0081,F-12511,L0081 |
|
|
Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high pote... |
|
T61430 |
S-2E
|
|
|
|
S-2E is a compound that functions as an orally active, noncompetitive inhibitor of both HMG-CoA reductase and acetyl-CoA carboxylase. It exhibits an anti-hyperlipidemic action, making it suitable for studying conditions ... |
|
T81918 |
Lodelcizumab
|
|
|
|
Lodelcizumab, a monoclonal antibody, is utilized in the study of hypercholesterolemia [1]. |
|
T77113 |
Ongericimab
|
|
|
|
Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9 with demonstrated lipid-lowering efficacy. It is utilized in the research of hypercholesterolemia and hyperlipidemia [1]. |
|
T35724 |
4-hydroxy Atorvastatin (calcium salt)
|
|
|
|
4-hydroxy Atorvastatin is a metabolite of atorvastatin , an HMG-CoA reductase inhibitor present in formulations that have been used to treat hypercholesterolemia and certain dyslipidemias. Atorvastatin is metabolized by ... |
|
T60579 |
CEase-IN-1
|
|
|
|
CEase-IN-1 (Compound A1H3) is a potent and selective inhibitor of cholesterol esterase (CEase) with an IC 50 of 0.36 μM. It can be used in hypercholesterolemia research [1]. |
|
T79052 |
PCSK9-IN-16
|
|
|
|
PCSK9-IN-16, holds potential for research into hypercholesterolemia and other cardiovascular diseases [1]. |
|
T82695 |
Colestilan
|
MCI-196,Colestimide |
|
|
Colestilan (MCI-196), a non-absorbable, non-calcium-based phosphate binder and anion exchange resin, exhibits oral activity and is utilized in the study of hypercholesterolemia [1] [2]. |
|
T74730 |
SPC4061
|
|
|
|
SPC4061, a potent PCSK9 inhibitor and an antisense nucleotide, specifically targets the lock-in nucleic acid (LNA) of PCSK9. This action is relevant for researching hypercholesterolemia and associated diseases [1] [2]. |
|
T79520 |
HMG-CoA Reductase-IN-1
|
|
|
|
HMG-CoA Reductase-IN-1 is an inhibitor of HMG-CoA reductase, demonstrating strong inhibitory activity on HMGR and affinity for OATP1B1, with pIC50 and pKm values of 8.54 and 1.98, respectively. It is utilized in hypercho... |
|
T77058 |
Lerodalcibep
|
|
|
|
Lerodalcibep (LIB003), a lipid-lowering agent, consists of a PCSK9-binding domain (adnectin) fused with human serum albumin, forming a recombinant fusion protein. It is utilized in the research of hypercholesterolemia an... |
|
T74720 |
Mipomersen
|
|
|
|
Mipomersen (ISIS 301012 free base), an antisense oligonucleotide inhibitor of apolipoprotein B (apoB), exhibits an anti-HCV effect and reduces the infectivity of HCV. It is used in research targeting homozygous familial ... |
|
T63515 |
THR-β agonist 4
|
|
|
|
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has shown research potential for metabolic diseases such as hyperlipidemia, obesity, hypercholesterolemia, diabetes and other conditions such as steatosis and... |
|
T77144 |
Recaticimab
|
|
|
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance the degradation of this enzyme. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte... |
|
T76974 |
Tafolecimab
|
|
|
|
Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting i... |
|
T63697 |
THR-β agonist 3
|
|
|
|
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has shown research potential for metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and... |
|
TP1984 |
[D-Trp34]-Neuropeptide Y
|
|
|
|
Potent neuropeptide Y (NPY) Y5 receptor agonist (pEC50 values are 7.82, 6.28, 6.44 and > 6 at rat Y5, Y4, Y1 and Y2 receptors respectively) that displays > 26-fold, > 1000-fold and > 1000-fold selectivity over Y1, Y2 and... |
